Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
OXGN > SEC Filings for OXGN > Form 8-K on 20-Sep-2013All Recent SEC Filings

Show all filings for OXIGENE INC

Form 8-K for OXIGENE INC


20-Sep-2013

Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, M


Item 1.01 Entry into a Material Definitive Agreement

On September 18, 2013, OXiGENE, Inc., a Delaware corporation ("OXiGENE"), entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain institutional investors, pursuant to which OXiGENE agreed to sell, in a private placement, an aggregate of 5,800 shares of its zero coupon Series B convertible preferred stock, par value $0.01 per share ("Series B Preferred Stock"), and Warrants ("Warrants") to purchase shares of its common stock, par value $0.01 per share ("Common Stock"), for an aggregate purchase price of $5,800,000 (the "Offering"). The closing of the Offering is expected to occur on or about September 23, 2013, subject to satisfaction of customary closing conditions set forth in the Purchase Agreement. The Purchase Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature. The Series B Preferred Stock does not have a dividend right, nor does it have any preferences over the Common Stock, including liquidation rights.

Subject to certain ownership limitations, shares of Series B Preferred Stock are convertible, at the option of the holder thereof, into an aggregate of up to 2.45 million shares of Common Stock, and the Warrants are exercisable to purchase up to 2.45 million shares of Common Stock. Each Warrant has an exercise price of $2.24 per share. The Warrants are immediately exercisable and expire five years after issuance.

OXiGENE has also entered into a Registration Rights Agreement with the investors pursuant to which OXiGENE is obligated to file a registration statement to register the resale of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock and upon exercise of the Warrants within fifteen calendar days.

OXiGENE entered into a letter agreement with H.C. Wainwright & Co. (the "Placement Agent"), dated September 18, 2013, pursuant to which the Placement Agent agreed to serve as the agent for OXiGENE in connection with the Offering. OXiGENE agreed to pay the Placement Agent a cash placement fee equal to 6% of the aggregate purchase price for the securities sold in the Offering, plus a non-accountable expense allowance equal to 1% of the gross proceeds of all securities sold in the Offering, not to exceed $50,000. In addition, upon the closing of the Offering, OXiGENE will pay the Placement Agent a cash fee payable within 48 hours of the receipt by OXiGENE of any proceeds from the cash exercise of the Series B warrants issued by OXiGENE in its private placement completed in April 2013, equal to 6% of the aggregate cash exercise price received by OXiGENE if the exercise is solicited by the Placement Agent. The Placement Agent will also receive warrants equal to 6% of the aggregate number of shares underlying the convertible securities sold in the Offering. In addition, OXiGENE will pay a cash fee equal to 6.5% of the aggregate purchase price for the securities sold in the Offering to Geller Biopharm, a healthcare investment banking division of Financial West Group.

In connection with OXiGENE's entry into the Purchase Agreement and the Registration Rights Agreement, OXiGENE will also enter into Amendment No. 7 to OXiGENE's Stockholder Rights Agreement ("Amendment No. 7") with American Stock Transfer & Trust Company, LLC, dated as of March 24, 2005, as amended (the "Stockholder Rights Agreement"), in order to exempt the issuances of securities that will be issued to the purchasers under the Purchase Agreement from the operation of the Stockholder Rights Agreement.

The foregoing descriptions of the Purchase Agreement, the Registration Rights Agreement, the Warrants, Amendment No. 7, and the letter agreement with the Placement Agent are subject to, and qualified in their entirety by, such documents attached hereto as Exhibits 10.1, 10.2, 4.1, 4.2 and 1.1, respectively, which are incorporated herein by reference.

As of August 31, 2013, the Company's net tangible book value per share was approximately $2.25.



Item 3.02 Unregistered Sales of Equity Securities.

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. The issuance and sale of securities by OXiGENE under the Purchase Agreement is exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.



Item 3.03 Material Modifications to Rights of Security Holders.

On September 19, 2013, OXiGENE filed the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the "Certificate of Designation") with the Secretary of State of the State of Delaware, establishing and designating the Series B Preferred Stock. Each share of Series B Preferred Stock has a stated value of $1,000. Each share of Series B Preferred Stock is convertible, at any time at the option of the holder thereof, into a number of shares of Common Stock determined by dividing the stated value by the conversion price of $2.365, subject to a 9.99% blocker provision. The Series B Preferred Stock has no dividend rights, liquidation preference or other preferences over Common Stock and has no voting rights except as provided in the Certificate of Designation or as otherwise required by law. A copy of the Certificate of Designation is attached hereto as Exhibit 3.1 and incorporated herein by reference. The foregoing description of the Certificate of Designation is qualified in its entirety by reference to Exhibit 3.1 attached hereto.

OXiGENE will use $2,800,000 of the net proceeds of the Offering to redeem all of the outstanding shares of Series A Preferred Stock issued by OXiGENE in its private placement completed in April 2013 at a cash redemption price equal to the aggregate stated value of such Series A Preferred Stock.




Item 5.03 Amendments to Articles of Incorporation or Bylaws.

On September 19, 2013, OXiGENE filed the Certificate of Designation, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference. The Certificate of Designation, effective as of September 19, 2013, establishes and designates the Series B Preferred Stock and the rights, preferences, privileges and limitations thereof.

Safe Harbor Statement

This Current Report on Form 8-K contains forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, unforeseen changes in the course of OXiGENE's research and development activities and clinical trials; the satisfaction of the closing conditions to the Offering; the conversion of Series B Preferred Stock or exercise of the Warrants, if issued; any increase in OXiGENE's cash needs; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in OXiGENE's periodic reports filed with the Securities and Exchange Commission. OXiGENE undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
  No.                                     Description

 1.1         Letter agreement dated as of September 18, 2013, by and between
             OXiGENE, Inc. and H.C. Wainwright & Co.

 3.1         Certificate of Designation of Preferences, Rights and Limitations of
             Series B Convertible Preferred Stock.

 4.1         Form of Common Stock Purchase Warrant.

 4.2         Form of Amendment No. 7 to Stockholder Rights Agreement, dated as of
             September 20, 2013, by and between the Company and American Stock
             Transfer & Trust Company, LLC.

10.1         Form of Securities Purchase Agreement dated as of September 18, 2013,
             by and among OXiGENE, Inc. and the purchasers named therein.

10.2         Form of Registration Rights Agreement dated as of September 18, 2013,
             by and among OXiGENE, Inc. and the purchasers named therein.


  Add OXGN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for OXGN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.